Action,ActionId,AuthorityGroup,Company,CompanyId,Country,CountryId,Drug,DrugId,EntityType,HighestDevStatus,HighestDevStatusForInd,HighestDevStatusForIndId,HighestDevStatusId,Indication,IndicationId,IsActiveCompany,LatestChange,ParentCompany,ParentCompanyId,Status,StatusDate,StatusId,StatusSortCode,TherapyArea,TherapyAreaId
Factor VIIa agonist,419,LOCAL_AND_MAJOR,PolyTherics Ltd,1002460,UK,GB,"PEGylated Factor VIIa (TheraPEG, hemophilia), PolyTherics/Pro Bono Bio/Cantab",76707,Biological,Discovery,Discovery,DR,DR,Hemophilia,439,true,2014-01-20 00:00:00,Abzena plc,1096483,Discovery,2012-05-29 00:00:00,DR,6,Hematological disease,142
Factor VIIa agonist,419,OTHER,Cantab Biopharmaceuticals Ltd,15303,UK,GB,"PEGylated Factor VIIa (TheraPEG, hemophilia), PolyTherics/Pro Bono Bio/Cantab",76707,Biological,Discovery,Discovery,DR,DR,Hemophilia,439,false,2014-01-20 00:00:00,Celtic Pharmaceutical Holdings LP,1014955,Discovery,2012-07-20 00:00:00,DR,6,Hematological disease,142
Factor VIIa agonist,419,LOCAL_AND_MAJOR,Pro Bono Bio,1068320,UK,GB,"PEGylated Factor VIIa (TheraPEG, hemophilia), PolyTherics/Pro Bono Bio/Cantab",76707,Biological,Discovery,Discovery,DR,DR,Hemophilia,439,true,2014-01-20 00:00:00,Pro Bono Bio,1068320,Discovery,2012-03-19 00:00:00,DR,6,Hematological disease,142
Factor VIIa agonist,419,OTHER,Cantab Biopharmaceuticals Ltd,15303,UK,GB,"PEGylated Factor VIIa (TheraPEG, hemophilia), PolyTherics/Pro Bono Bio/Cantab",76707,Biological,Discovery,Discovery,DR,DR,Hemophilia,439,false,2014-01-20 00:00:00,Celtic Pharmaceutical Holdings LP,1014955,No Development Reported,2014-01-20 00:00:00,NDR,2,Hematological disease,142